World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
73
Citations
19094
World Ranking
2140
National Ranking
189

Robin J. Shattock publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Robin J. Shattock sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 364 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Robin J. Shattock D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Robin J. Shattock sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Robin J. Shattock is a researcher affiliated with Imperial College London in the United Kingdom. Their work spans medicine, biochemistry, genetics, molecular biology, immunology, microbiology, and infectious diseases. Key subfields include molecular biology, immunology, virology, and epidemiology.

The scientist's research primarily focuses on several main topics: SARS-CoV-2 and COVID-19 research, RNA interference and gene delivery, HIV research and treatment, advanced biosensing and bioanalysis techniques, immunotherapy and immune responses, animal virus infections studies, and SARS-CoV-2 detection and testing.

Shattock has published extensively in a variety of scientific venues. Frequent publication outlets include bioRxiv (Cold Spring Harbor Laboratory), Vaccines, npj Vaccines, Frontiers in Immunology, and Molecular Therapy - Nucleic Acids.

Collaborations have been a significant aspect of Shattock's scientific output. Frequent co-authors include Paul F. McKay, Anna K. Blakney, Karnyart Samnuan, Hannah M. Cheeseman, and Kai Hu.

Notable recent papers illustrate the research scope and areas of focus:

  • "Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice" (2020, Nature Communications)
  • "Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey" (2020, Thorax)
  • "Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial" (2022, EClinicalMedicine)
  • "Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer" (2020, ACS Nano)
  • "Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand" (2020, Vaccines)

Best Publications

  • In vitro and in vivo: the story of nonoxynol 9.

    Sharon L Hillier;Thomas Moench;Robin Shattock;Roberta Black

  • Inhibiting sexual transmission of HIV-1 infection

    Robin J. Shattock;John P. Moore

  • Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120

    Ronald S. Veazey;Robin J. Shattock;Melissa Pope;J. Christian Kirijan

  • Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.

    Paul F. McKay;Kai Hu;Anna K. Blakney;Karnyart Samnuan

  • Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.

    Peter Greenhead;Peter Hayes;Patricia S. Watts;Ken G. Laing

  • Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of their Replication Capacity in CD4 T-Lymphocytes and Monocyte-derived Macrophages

    Christina Ochsenbauer;Tara G. Edmonds;Haitao Ding;Brandon F. Keele

  • Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.

    Ronald S. Veazey;Per Johan Klasse;Susan M. Schader;Qinxue Hu

  • Target cells in vaginal HIV transmission.

    Christopher J. Miller;Robin J. Shattock

  • Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component

    Barry R. O'Keefe;Fakhrieh Vojdani;Viviana Buffa;Robin J. Shattock

  • Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?

    Leonid Margolis;Robin Shattock

  • Cyanovirin-N Inhibits AIDS Virus Infections in Vaginal Transmission Models

    Che Chung Tsai;Peter Emau;Yonghou Jiang;Michael B. Agy

  • Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue

    Qinxue Hu;Ines Frank;Vennansha Williams;John J. Santos

  • Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells.

    J. S. Friedland;R. Shattock;D. G. Remick;G. E. Griffin

  • Antiretroviral Drug–Based Microbicides to Prevent HIV-1 Sexual Transmission

    Per Johan Klasse;Robin Shattock;John P. Moore

  • Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.

    Chang Li;Xinmeng Guan;Tao Du;Wei Jin

  • Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

    Unknown

  • Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

    Sonya Abraham;Helene B Juel;Peter Bang;Hannah M Cheeseman

  • Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter Study

    Raina N. Fichorova;Nicola Richardson-Harman;Massimo Alfano;Laurent Belec

  • Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA.

    Anna K Blakney;Paul F McKay;Bárbara Ibarzo Yus;Yoann Aldon

  • Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

    Martin Cranage;Sally Sharpe;Carolina Herrera;Alethea Cope

  • IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis.

    Asna A. Siddiqui;Annemarie E. Brouwer;Annemarie E. Brouwer;Vannaporn Wuthiekanun;Shabbar Jaffar

  • Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture.

    Zoltán Kis;Robin Shattock;Nilay Shah;Cleo Kontoravdi

  • Selective transmission of R5 HIV-1 variants: where is the gatekeeper?

    Jean-Charles Grivel;Robin J Shattock;Leonid B Margolis

Frequent Co-Authors

George E. Griffin
George E. Griffin St George's, University of London
Jon S. Friedland
Jon S. Friedland St George's, University of London
John P. Moore
John P. Moore Cornell University
Leonid Margolis
Leonid Margolis National Institutes of Health
Gavin Andrews
Gavin Andrews University of New South Wales
Peter A. Anton
Peter A. Anton University of California, Los Angeles
Jean-Charles Grivel
Jean-Charles Grivel Sidra Medical and Research Center
Per Johan Klasse
Per Johan Klasse Cornell University
Thomas J. Hope
Thomas J. Hope Northwestern University
Sharon J. Peacock
Sharon J. Peacock University of Cambridge

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in immunology, expanding their qualifications with related healthcare degrees can open diverse career opportunities. Many professionals pursue nursing pathways that complement immunological expertise, such as becoming a psychiatric nurse practitioner. Affordable PMHNP programs offer cost-effective routes to specialize in mental health, a sector closely linked to immune system studies.

Nurses holding a Doctor of Nursing Practice (DNP) degree can also benefit from understanding salary prospects by state, helping them make informed decisions about where to advance their careers. The data on doctorate in nursing salary highlights the potential financial rewards, motivating many to pursue advanced roles combining clinical and immunological knowledge.

Transitioning from a Family Nurse Practitioner (FNP) to an Acute Care Nurse Practitioner (ACNP) is another valuable pathway. Online bridge programs, like the FNP to ACNP bridge program online, enable working nurses to acquire acute care skills without pausing their careers, aligning well with clinical immunology applications in acute and critical care settings.

For those seeking a quicker entry into nursing specialties, accelerated FNP programs provide intensive, streamlined education paths. These programs support faster transitions into family nursing roles that often intersect with primary immunological care and prevention.

Best Scientists Citing Robin J. Shattock

Trending Scientists